Profluent entered into an agreement valued at over $2 billion with Eli Lilly to bring AI-generated proteins into clinical development

Artificial intelligence applications across healthcare, covering clinical decision support, diagnostics, workflow automation, drug discovery, patient monitoring, safety risks, equity concerns, and regulation.